Literature DB >> 6688430

Structure-activity relationships of heparin. Independence of heparin charge density and antithrombin-binding domains in thrombin inhibition by antithrombin and heparin cofactor II.

R E Hurst, M C Poon, M J Griffith.   

Abstract

To better understand how heparin structure affects its activity the relationships between the functional domains for inhibitor binding and charge density were investigated to determine how these domains affect heparin-mediated thrombin inhibition by two different heparin-dependent protease inhibitors, antithrombin (AT) and heparin cofactor II (HC II). A series of heparins, fractionated systematically by charge density, was further fractionated on antithrombin agarose to isolate more homogeneous subfractions that were either inactive or highly active with respect to thrombin inhibition by AT. With AT, the activities of the AT-active subfractions increased sharply with heparin charge density, while those with little or no affinity for AT were virtually inactive. In contrast, with HC II inhibitor, the activities of the heparins depended only upon their charge densities and were independent of AT affinity. At any given charge density, the heparin before fractionation by AT affinity and the fractions that were highly active and inactive with AT were all equally active with HC II. The two inhibitors also differed in their reactivity with heparan sulfate and dermatan sulfate. A charge-density effect with the subfractions having similar high affinity for AT demonstrates that charge density represents a heparin functional domain that is independent of the AT-binding domain. The behavior of the AT-inactive heparins, being fully active with HC II, demonstrates the functional domain necessary for AT binding is not needed to produce HC II activity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6688430      PMCID: PMC1129271          DOI: 10.1172/JCI111028

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  16 in total

1.  Thrombin.

Authors:  R L Lundblad; H S Kingdon; K G Mann
Journal:  Methods Enzymol       Date:  1976       Impact factor: 1.600

2.  The separation of active and inactive forms of heparin.

Authors:  L H Lam; J E Silbert; R D Rosenberg
Journal:  Biochem Biophys Res Commun       Date:  1976-03-22       Impact factor: 3.575

3.  Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin.

Authors:  M Höök; I Björk; J Hopwood; U Lindahl
Journal:  FEBS Lett       Date:  1976-07-01       Impact factor: 4.124

4.  Properties of antithrombin III depleted plasma. I. Effect of heparin.

Authors:  E Holmer; G Söderström; L O Andersson
Journal:  Thromb Res       Date:  1980 Jan 1-15       Impact factor: 3.944

5.  The molecular-weight-dependence of the anti-coagulant activity of heparin.

Authors:  T C Laurent; A Tengblad; L Thunberg; M Höök; U Lindahl
Journal:  Biochem J       Date:  1978-11-01       Impact factor: 3.857

6.  Kinetic analysis of the heparin-enhanced antithrombin III/thrombin reaction. Reaction rate enhancement by heparin-thrombin association.

Authors:  M J Griffith
Journal:  J Biol Chem       Date:  1979-12-10       Impact factor: 5.157

7.  Structural basis for the anticoagulant activity of heparin. 2. Relationship of anticoagulant activity to the thermodynamics and fluorescence fading kinetics of acridine orange-heparin complexes.

Authors:  J M Menter; R E Hurst; D A Corliss; S S West; E W Abrahamson
Journal:  Biochemistry       Date:  1979-10-02       Impact factor: 3.162

8.  Structural basis for the anticoagulant activity of heparin. 1. Relationship to the number of charged groups.

Authors:  R E Hurst; J M Menter; S S West; J M Settine; E H Coyne
Journal:  Biochemistry       Date:  1979-10-02       Impact factor: 3.162

9.  Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin.

Authors:  U Lindahl; G Bäckström; L Thunberg; I G Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

10.  The anticoagulant activity of dermatan sulphates: evidence against the involvement of antithrombin III.

Authors:  G Kindness; W F Long; F B Williamson
Journal:  Br J Pharmacol       Date:  1981-01       Impact factor: 8.739

View more
  11 in total

Review 1.  Tissue Engineering at the Blood-Contacting Surface: A Review of Challenges and Strategies in Vascular Graft Development.

Authors:  Daniel Radke; Wenkai Jia; Dhavan Sharma; Kemin Fena; Guifang Wang; Jeremy Goldman; Feng Zhao
Journal:  Adv Healthc Mater       Date:  2018-05-07       Impact factor: 9.933

2.  Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II.

Authors:  M F Scully; V Ellis; N Seno; V V Kakkar
Journal:  Biochem J       Date:  1988-09-01       Impact factor: 3.857

Review 3.  Glycosaminoglycans and the regulation of blood coagulation.

Authors:  M C Bourin; U Lindahl
Journal:  Biochem J       Date:  1993-01-15       Impact factor: 3.857

4.  Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4.

Authors:  D M Tollefsen; C A Pestka
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

5.  Heparin is a major activator of the anticoagulant serpin, protein Z-dependent protease inhibitor.

Authors:  Xin Huang; Alireza R Rezaie; George J Broze; Steven T Olson
Journal:  J Biol Chem       Date:  2011-01-10       Impact factor: 5.157

Review 6.  Low molecular weight heparins. An objective overview.

Authors:  D Hoppensteadt; J M Walenga; J Fareed
Journal:  Drugs Aging       Date:  1992 Sep-Oct       Impact factor: 3.923

Review 7.  Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract.

Authors:  R E Hurst
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

8.  Endothelial binding sites for heparin. Specificity and role in heparin neutralization.

Authors:  T Bârzu; J L Van Rijn; M Petitou; P Molho; G Tobelem; J P Caen
Journal:  Biochem J       Date:  1986-09-15       Impact factor: 3.857

9.  Effect of a pentosan polysulphate upon thrombin and factor Xa inactivation by antithrombin III.

Authors:  M F Scully; V V Kakkar
Journal:  Biochem J       Date:  1984-09-15       Impact factor: 3.857

10.  A heparin binding synthetic peptide from human HIP / RPL29 fails to specifically differentiate between anticoagulantly active and inactive species of heparin.

Authors:  David E Hoke; Daniel D Carson; Magnus Höök
Journal:  J Negat Results Biomed       Date:  2003-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.